Skip to main content
Evidence Snapshot

D(1B) dopamine receptor

CHEMBL1850 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T01:52:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1850
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats D(1B) dopamine receptor as ChEMBL target CHEMBL1850, mapped to UniProt P21918. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
D(1B) dopamine receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL1850
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21918
D(1B) dopamine receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why D(1B) dopamine receptor matters

As of 2026-09-13

D(1B) dopamine receptor is reviewed as D(1B) dopamine receptor (UniProt P21918); D(1B) dopamine receptor shows late clinical disease relevance led by Parkinson disease. 2 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 22 approved drugs, 1427 compounds, and 271 assays, with lead potency reaching pChEMBL 10.3.

Disease context
Parkinson disease

D(1B) dopamine receptor shows late clinical disease relevance led by Parkinson disease. 2 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 2 additional disease programs remain visible in the same card. Linked drugs include TAVAPADON.

Start review with Parkinson disease because it currently carries late clinical support. Linked drugs include TAVAPADON. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Late clinical 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 22 approved drugs, 1427 compounds, and 271 assays for this target. The dominant activity type is KI. CHEMBL203637 is the current potency anchor at pChEMBL 10.3.

Use CHEMBL203637 as the tractability anchor when discussing potency (pChEMBL 10.3).

Activity source · ChEMBL 36 via Core Engine
22 approved pChEMBL 10.3
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why D(1B) dopamine receptor matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P21918, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why Parkinson disease is currently treated as late clinical support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

1427
Total Compounds
271
Total Assays
22
Approved Drugs
IC50: 21.0, KI: 830.0, EC50: 35.0, KD: 4.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL203637
 10.3 Ki —
No preferred name
CHEMBL1814790
 9.8 IC50 —
No preferred name
CHEMBL1814790
 9.8 Ki —
No preferred name
CHEMBL245764
 9.6 Ki —
No preferred name
CHEMBL5207281
 9.6 Kd —

Approved Drugs

Structure Compound First Approval
LASMIDITAN
CHEMBL3039520
 2020
BREXPIPRAZOLE
CHEMBL2105760
 2015
PALIPERIDONE
CHEMBL1621
 2006
APOMORPHINE
CHEMBL53
 2001
OLANZAPINE
CHEMBL715
 1996
RISPERIDONE
CHEMBL85
 1993
CLOZAPINE
CHEMBL42
 1989
MAPROTILINE
CHEMBL21731
 1980
DOPAMINE
CHEMBL59
 1974
CHLORPROTHIXENE
CHEMBL908
 1967
HALOPERIDOL
CHEMBL54
 1967
AMITRIPTYLINE
CHEMBL629
 1961
FLUPHENAZINE
CHEMBL726
 1959
CHLORPROMAZINE
CHEMBL71
 1957
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T01:52:02Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL1850